Browse Studies — Arctuva

Phase 2

A Phase 2, Open-Label, Single-Arm, Sequential-Panel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Posaconazole (POS, MK-5592) Intravenous and Powder for Oral Suspension Formulations in Pediatric Participants From Birth to Less Than 2 Years of Age With Possible, Probable, or Proven Invasive Fungal Infection

This study aims to estimate the pharmacokinetics (PK) of posaconazole (POS, MK-5592) intravenous (IV) and powder for oral suspension (PFS) formulations in pedi…

Invasive Fungal Infection

Estimated

~$10 – $8,750

Find your next paid study

Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections